Article Text

Download PDFPDF
21 The effects of lumbar sympathetic ganglion block therapy on secondary lower limb lymphedema in patients with gynecological cancer surgery
  1. Yang Sun,
  2. Jie Lin,
  3. Huaqing Huang and
  4. Huizhe Zheng
  1. Fujian Cancer Hospital, Fuzhou, China


Introduction/Background Secondary lower limb lymphedema (LLL) is a frequently reported complication in women with gynecological cancer surgery, which can have serious physical and psychological consequences. Although complex decongestive physical therapy(CDT) is widely used, the optimal treatment is still unknown. Lumbar sympathetic ganglion block (LSGB) is a treatment involving injecting a drug mixture around the sympathetic trunk. Few studies focus on the use of LSGB for limb lymphedema. Hence, we aimed to investigate the clinical effect of LSGB in gynecological cancer patients with secondary LLL and to explore its impact on life quality.

Methodology We included 94 gynecological cancer survivors with stage two LLL who received either CDT or CDT combined with LSGB treatment between September 2021 and September 2023 in our hospital. Fluoroscopy-guided LSGB, two times at 3-day intervals, was extra performed in CDT+LSGB groups. Clinical data was retrospectively analyzed. Circumferences of five leg points, including thigh 1, thigh 2, calf, ankle, and foot, were assessed on the first day and one week after treatment. The Lymphedema Quality of Life Questionnaire-LEG (LYMQOL-LEG) was monitored before and after treatment.

Results There were 36 patients in the CDT group and 58 in the CDT+LSGB group. The leg circumferences of thigh 1, thigh 2, and calf decreased more in the CDT+LSGB group than in CDT groups (P thigh 1 =0.028; P thigh 2 =0.017; and P calf= 0.019;). Although the circumferences of ankle and foot showed no difference in the two groups(P ankle= 0.240; P foot = 0.307), the total length of five regressions in the CDT+LSGB group was still better than that of CDT groups (P =0.030). On the other hand, the life quality improved more in patients with CDT+LSGB treatment compared with CDT treatment alone (P <0.05).

Conclusion LSGB can be a safe and effective treatment option for gynecological cancer survivors with secondary LLL.

Disclosures This work was sponsored by the Joint Funds for the Innovation of Science and Technology, Fujian Province (Grant number 2021Y9209) and the Fujian Provincial Health Technology Project (Grant number 2021QNA043). The authors declare no competing financial interests.

Abstract 21 Figure 1

Patient selection

Abstract 21 Figure 2

The measurement points

Abstract 21 Figure 3

Fluoroscopic image SLGB

Abstract 21 Figure 4

Outcomes of CDT+LSGB A Before; B After

Abstract 21 Table 1

The regression of LLL during treatment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.